Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Sponsor : Eurostars
Deal Size : Undisclosed
Deal Type : Funding
Phenocell, Amarna Win Grant To Study Gene Therapy for Dry AMD Using Retinal Model
Details : Eurostars' funding will support their collaboration to validate Amarna's patented gene therapy platform using a novel and advanced cellular disease model for Dry AMD.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Sponsor : Eurostars
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Nimvec AM510
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : NorthX Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Amarna Partners with NorthX to Advance Nimvec™ AM510 Gene Therapy Program
Details : The partnership focuses on advancing the clinical trial manufacturing of Nimvec AM510, Amarna’s groundbreaking gene therapy platform designed to transform the treatment of type 1 diabetes.
Product Name : Nimvec AM510
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2024
Lead Product(s) : Nimvec AM510
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : NorthX Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AMA005
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : C4 holding BV
Deal Size : $5.7 million
Deal Type : Financing
Details : The funds will enable Amarna to advance its lead gene therapy AMA005, for the treatment of hemophilia B towards a first-in-human clinical trial, and to progress its R&D pipeline in selected autoimmune diseases and chronic inflammation.
Product Name : AMA005
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 12, 2021
Lead Product(s) : AMA005
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : C4 holding BV
Deal Size : $5.7 million
Deal Type : Financing